Gowling WLG advised Sosei Heptares on a multi-million pound drug with Boehringer Ingleheim. Sosei Heptares, a leading biopharmaceutical company, has joined forces with Boehringer Ingelheim in...
You must be a Standard 1 Year member to access this content.
Orrick advised Sosei Heptares. Sosei Heptares has announced its acquisition for U.S.$466 million (JPY 65 billion) of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China). Sosei...
You must be a Standard 1 Year member to access this content.
Gowling WLG advised Sosei Heptares. Sosei Heptares signed a collaboration and license agreement with Eli Lilly to develop new treatments in diabetes and metabolic diseases. The...
You must be a Standard 1 Year member to access this content.
Gowling WLG’s advised Sosei Heptares on the deal. Sosei Heptares on its collaboration with San Diego based Neurocrine Biosciences Inc to develop novel muscarinic receptor agonist...
You must be a Standard 1 Year member to access this content.
